Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.48M | $4.00M | $8.39M | $4.46M | $1.05M | $2.96M | $1.77M | $314K | $302K | $70.8M |
| Revenue growth | — | 15.1% | 109.5% | -46.8% | -76.5% | 182.2% | -40.2% | -82.3% | -3.8% | 23359.9% |
| Operating income | -$17.0M | -$26.5M | -$33.1M | -$42.0M | -$110M | -$79.7M | -$134M | -$254M | -$299M | -$363M |
| Operating margin | -488.6% | -662.8% | -394.5% | -941.0% | -10512.4% | -2690.8% | -7579.2% | -81035.0% | -99018.2% | -512.9% |
| Net income | -$17.3M | -$26.5M | -$32.7M | -$41.9M | -$111M | -$79.4M | -$130M | -$238M | -$270M | -$343M |
| Net margin | -496.8% | -662.3% | -390.0% | -938.6% | -10544.3% | -2680.2% | -7329.2% | -75711.5% | -89387.1% | -483.6% |
| EPS (diluted) | -$28.21 | -$1.38 | -$1.10 | -$20.04 | -$31.13 | -$6.66 | -$4.05 | -$5.31 | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.8M | -$28.2M | -$26.8M | -$36.1M | -$29.8M | -$54.6M | -$93.8M | -$184M | -$232M | -$276M |
| Capital expenditures | $250K | $246K | $445K | $84.0K | $42.0K | $338K | $797K | $898K | $511K | $495K |
| Free cash flow | -$15.0M | -$28.4M | -$27.3M | -$36.1M | -$29.8M | -$54.9M | -$94.6M | -$185M | -$233M | -$277M |
| Share buybacks | $2.00K | — | — | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $22.1M | $47.4M | $32.6M | $24.8M | $45.9M | $42.3M | $156M | $103M | $99.6M | $212M |
| Total assets | $24.8M | $52.5M | $66.1M | $30.3M | $131M | $204M | $435M | $490M | $742M | $899M |
| Total liabilities | $9.71M | $14.0M | $14.8M | $14.5M | $11.2M | $16.0M | $40.0M | $48.4M | $70.8M | $177M |
| Long-term debt | — | $10.0M | $10.0M | $7.67M | — | $0.00 | $4.64M | $20.2M | $20.6M | — |
| Shareholders' equity | -$61.9M | $38.5M | $51.3M | $15.8M | $120M | $188M | $395M | $442M | $672M | $722M |
| Retained earnings | -$67.1M | -$93.6M | -$126M | -$168M | -$279M | -$358M | -$488M | -$726M | -$996M | -$1.34B |
| Shares (wtd avg diluted) | 834K | 22.6M | 30.8M | 2.32M | 4.23M | 23.9M | 41.3M | 54.0M | 81.0M | 102M |
Every figure is extracted from Viridian Therapeutics, Inc.DE’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.